drugset / Trial / NCT00723359
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2008-08
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INDATUXIMAB RAVTANSINE | Unknown | — | — |